Nader Iskander, MD
Ophthalmology · San Antonio, TXNPI 1659369601
Payments from drug & device makers
Across 200 payments — averaging $201.48 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Rxsight Inc$30K
- Johnson & Johnson Surgical Vision, Inc.$3K
- Alcon$919
- Biotissue Holdings Inc.$901
- Bausch & Lomb, A Division Of Bausch Health US, LLC$888
- AbbVie$797
- plus $4K from 25 others
What the payments were for
- Consulting fees$4,53236%
- Speaking & faculty fees$260%
- Food & beverage$7,88863%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Rxsight Inc | 14 | $30,252 |
| Johnson & Johnson Surgical Vision, Inc. | 12 | $2,906 |
| Alcon | 15 | $919 |
| Biotissue Holdings Inc. | 10 | $901 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 23 | $888 |
| AbbVie(2 entities) | 23 | $797 |
| Novartis | 19 | $534 |
| Bausch & Lomb Americas Inc. | 14 | $484 |
| Sun Pharmaceutical Industries Inc. | 17 | $473 |
| Tarsus Pharmaceuticals, Inc. | 7 | $267 |
| Genentech USA, Inc. | 2 | $242 |
| Ocular Therapeutix, Inc. | 6 | $175 |
| Shire North American Group Inc | 4 | $168 |
| Eyevance Pharmaceuticals LLC | 1 | $125 |
| AstraZeneca | 1 | $125 |
| Carl Zeiss Meditec, Inc. | 1 | $120 |
| Lensar, Inc. | 3 | $119 |
| Pacira Pharmaceuticals Incorporated | 1 | $113 |
| Mallinckrodt Hospital Products Inc. | 5 | $109 |
| Amgen | 1 | $108 |
| Oyster Point Pharma, Inc. | 4 | $79 |
| Staar Surgical Company | 1 | $75 |
| Rayner Intraocular Lenses Limited | 3 | $62 |
| Omeros Corporation | 3 | $54 |
| Dompe US, Inc. | 3 | $51 |
| Carl Zeiss Meditec USA, Inc. | 1 | $51 |
| Thea Pharma Inc. | 1 | $25 |
| Aerie Pharmaceuticals, Inc. | 1 | $21 |
| NEW World Medical,inc. | 1 | $20 |
| Harrow Eye, LLC | 1 | $18 |
| Tearlab Corp | 2 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- RXSIGHT CONTACT LENS$3,214
- RXSIGHT INJECTOR CARTRIDGE$3,214
- RXSIGHT INJECTOR HANDPIECE$3,214
- RXSIGHT LIGHT DELIVERY DEVICE (LDD)$3,214
- LIGHT ADJUSTABLE LENS (LAL)$2,101
- Tecnis Symfony IOL$1,532
- RXSIGHT LIGHT ADJUSTABLE LENS (RXLAL)$1,113
- Clareon$282
- Centurion$267
- DURYSTA$255
- MIEBO$234
- XIIDRA$225
- MAYZENT$225
- Prokera$176
- AmnioGraft$176
- ENVISTA$150
- VABYSMO$125
- SOLIRIS$125
- Tobradex ST$125
- XDEMVY$121
How this compares
$40,296 in reported general payments places this provider in the 85th percentile of 1,355 ophthalmology providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RestasisCyclosporine | 17 | $26,727 |
| Prednisolone Acetate | 338 | $13,507 |
| Bromfenac Sodium | 65 | $11,436 |
| ProlensaBromfenac Sodium | 24 | $8,156 |
| Cyclosporine | 14 | $6,825 |
| VyzultaLatanoprostene Bunod | 11 | $5,924 |
| Latanoprost | 202 | $3,003 |
| Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol | 16 | $2,643 |
| Ofloxacin | 166 | $1,697 |
| Brimonidine Tartrate | 58 | $1,141 |
| Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat | 36 | $527 |
| Diclofenac Sodium | 45 | $431 |
| Timolol Maleate | 37 | $358 |
| Neomycin-Polymyxin-DexamethNeomycin/Polymyxin B/Dexametha | 31 | $279 |
| Dorzolamide Hcl | 14 | $160 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieRestasis | $797 | $26,72717 claims |
| Bausch & Lomb, A Division Of Bausch Health US, LLCProlensa | $888 | $8,15624 claims |
| Bausch & Lomb Americas Inc.Vyzulta | $484 | $5,92411 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 1,355 ophthalmology providers in Texas.
Other ophthalmology in San Antonio
- Michael SingerSan Antonio$4.2M
- Gregory ParkhurstSan Antonio$4.1M
- Calvin MeinSan Antonio$1.3M
- James LehmannSan Antonio$1.1M
- Darren BellSan Antonio$906K
- Gregory BruninSan Antonio$709K
- Richard EvansSan Antonio$656K
- Edward RashidSan Antonio$523K
- Kenneth MaverickSan Antonio$485K
- Kundandeep NagiSan Antonio$442K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.